<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113342</url>
  </required_header>
  <id_info>
    <org_study_id>DC25-1A</org_study_id>
    <nct_id>NCT05113342</nct_id>
  </id_info>
  <brief_title>Descartes-25 in Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cartesian Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cartesian Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and&#xD;
      preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting&#xD;
      a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple&#xD;
      Myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of Descartes-25</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate according to the IMWG response criteria</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Duration of Response</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Relapse Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Descartes-25</intervention_name>
    <description>An allogeneic Mesenchymal Stem Cell product.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years and older'&#xD;
&#xD;
          -  diagnosed with active R/RMM, who have failed 2 lines of treatment&#xD;
&#xD;
          -  have measurable disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patients with active plasma cell leukemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Chowdhury, MD, MBA</last_name>
    <phone>2404238999</phone>
    <email>adam.chowdhury@cartesiantx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Milo Miljkovic, MD, MS</last_name>
    <email>milos@cartesiantx.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myeloma</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>Relapse Refactory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

